Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue				$ 850,000
Costs and expenses:
Research and development	$ 3,843,000	$ 4,064,000	$ 6,809,000	9,577,000
General and administrative	1,558,000	1,605,000	3,186,000	3,182,000
Total costs and expenses	5,401,000	5,669,000	9,995,000	12,759,000
Loss from operations	(5,401,000)	(5,669,000)	(9,995,000)	(11,909,000)
Interest expense	(1,000)	(351,000)	(2,000)	(683,000)
Other income (expense), net	19,000	51,000	19,000	49,000
Loss before provision for income taxes	(5,383,000)	(5,969,000)	(9,978,000)	(12,543,000)
Provision for income taxes	0	0	0	0
Net loss	(5,383,000)	(5,969,000)	(9,978,000)	(12,543,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(5,383,000)	(5,969,000)	(9,978,000)	(12,543,000)
Comprehensive loss	$ (5,383,000)	$ (5,969,000)	$ (9,978,000)	$ (12,543,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic	$ (0.13)	$ (0.21)	$ (0.25)	$ (0.47)
Net loss per share attributable to Vaccinex, Inc. common stockholders, diluted	$ (0.13)	$ (0.21)	$ (0.25)	$ (0.47)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic	42,664,051	28,577,779	40,711,167	26,897,283
Weighted-average shares used in computing net loss per share attributable toVaccinex, Inc. common stockholders, diluted	42,664,051	28,577,779	40,711,167	26,897,283